ATOS – atossa therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen [Yahoo! Finance]
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
Atossa (ATOS) Reports Positive Results From EVANGELINE Study [Yahoo! Finance]
Form 4 ATOSSA THERAPEUTICS, For: Apr 10 Filed by: Finn Jonathan
Form 8-K/A ATOSSA THERAPEUTICS, For: Apr 01
Form 10-K ATOSSA THERAPEUTICS, For: Dec 31
Form 8-K ATOSSA THERAPEUTICS, For: Apr 01
Form 8-K ATOSSA THERAPEUTICS, For: Mar 15
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.